A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Recruiting

Phase 1

Phase 2

TransCon IL-2 β/γA Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Sponsor:

Ascendis Pharma Oncology Division A/S

Code:

NCT05081609

Conditions

Advanced Solid Tumor

Locally Advanced Solid Tumor

Metastatic Solid Tumor

Platinum-resistant Ovarian Cancer

Post Anti-PD-1 Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TransCon IL-2 β/γ

Pembrolizumab

Chemotherapy drug

TransCon TLR7/8 Agonist

Surgery

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-12. This information was provided to ClinicalTrials.gov by Ascendis Pharma Oncology Division A/S on 2025-07-08.